Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has appointed accomplished medical professional Dr Gavin Shepherd as an independent non-executive director with effect from today.
Dr Shepherd brings to Prescient the benefit of 25 years of experience in medicine and a proven track record in driving success in various specialist consulting businesses.
After completing his medical qualification at Flinders University, he completed specialist training as a consultant Occupational and Environmental Physician with a fellowship from the Royal Australasian College of Physicians. He completed his GAICD qualification in 2011 and is a non-executive director of Lateral Pharma Pty Ltd.
“Underscores company’s dedication”
“We are pleased to welcome Dr Shepherd to our Board of Directors," Prescient chair Steve Engle said.
"Prescient remains committed to advancing its innovative programs to address unmet medical needs.
"The addition of Gavin to the Board of Directors underscores the company’s dedication to strengthening its leadership team ahead of some catalysts for the company.”
Active healthcare contributor
Dr Shepherd, who said that he was honoured to join the Board of Directors at Prescient, combines his medical expertise with strong business acumen, demonstrated by his business success as well as through his investment in disruptive healthcare technologies.
He actively contributes to the healthcare industry through his involvement with the Medical Device Partnering Program at Flinders University and his lecturing for the Royal Australian College of General Practitioners registrar training program in South Australia.
“A strong conviction”
"I have closely followed the company's progress for several years and have developed a strong conviction in Prescient's intellectual property portfolio. This conviction led me to become a committed shareholder of PTX,” Dr Shepherd said.
"While the current market environment presents headwinds, I remain confident in Prescient's outlook and potential to improve health outcomes for cancer patients and their families.
"I look forward to working with the board and management to clinically progress this science for the benefit of both cancer sufferers and shareholders.”